# Zomedica Corp. (ZOMDF)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/zomedica-corp/ JSON: https://steadybase.io/company/zomedica-corp.json Checked Nov 10, 2026. Latest filing read: Nov 4, 2026.

## Company

- Legal name: Zomedica Corp.
- Ticker: ZOMDF (OTC)
- SEC CIK: 0001684144
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: Ann Arbor, MI
- Fiscal year ends: December 31
- SEC filer category: Non-accelerated filer<br>Smaller reporting company
- Website: zomedica.com
- Investor relations: https://investors.zomedica.com
- LinkedIn: https://www.linkedin.com/company/zomedica
- Next earnings date: Nov 20, 2026

## Key facts

- Revenue: $32.0M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 16, 2026). Source: https://www.sec.gov/Archives/edgar/data/1684144/000110465926028450/0001104659-26-028450-index.html
- Operating income: -$84.4M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 16, 2026). Source: https://www.sec.gov/Archives/edgar/data/1684144/000110465926028450/0001104659-26-028450-index.html
- Net income: -$81.9M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 16, 2026). Source: https://www.sec.gov/Archives/edgar/data/1684144/000110465926028450/0001104659-26-028450-index.html
- SG&A: $43.0M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 16, 2026). Source: https://www.sec.gov/Archives/edgar/data/1684144/000110465926028450/0001104659-26-028450-index.html
- Employees: 141 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1684144/000110465926028450/zom-20251231x10k.htm
- Shares outstanding: 979,949,668 as of Nov 4, 2026 (10-Q filed Nov 4, 2026). Source: https://www.sec.gov/Archives/edgar/data/1684144/000110465926122658/0001104659-26-122658-index.html
- Auditor: Grant Thornton LLP, Southfield, Michigan, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1684144/000110465926028450/zom-20251231x10k.htm

## Business

Zomedica Corp. (“Zomedica” or the “Company”) was incorporated on January 7, 2013 under the Business Corporations Act (Alberta) as Wise Oakwood Ventures Inc.4 of the TSX Venture Exchange. ZoMedica Pharmaceuticals Inc. (“ZoMedica”) was incorporated on May 14, 2015, under the Canada Business Corporations Act.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1684144/000110465926028450/zom-20251231x10k.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $32.0M | -$84.4M | -$81.9M | $43.0M |
| Dec 31, 2024 | $27.3M | -$51.1M | -$47.0M | $46.8M |
| Dec 31, 2023 | $25.2M | -$43.3M | -$34.5M | $43.2M |
| Dec 31, 2022 | $18.9M | -$21.9M | -$17.0M | $33.0M |
| Dec 31, 2021 | $4.1M | -$21.4M | -$18.4M | $22.8M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/zomedica-corp.json

## Officers and directors

- Larry Heaton, Chief Executive Officer of Zomedica. Source: 8-K filed Nov 4, 2026, https://www.sec.gov/Archives/edgar/data/1684144/000165495426009511/zom_ex991.htm
- Larry C. Heaton Ii, CEO. LinkedIn: https://linkedin.com/in/lcheatonii. Source: Form 4 filed May 8, 2026, https://www.sec.gov/Archives/edgar/data/1684144/000165495426004631/0001654954-26-004631-index.htm
- Anthony K. Blair, COO. Source: Form 4 filed Aug 7, 2026, https://www.sec.gov/Archives/edgar/data/1684144/000165495426007397/0001654954-26-007397-index.htm
- Michael Zuehlke, Vice President of Finance and Corporate Controller (Principal Financial and Accounting Officer). Source: 10-Q filed Nov 4, 2026, https://www.sec.gov/Archives/edgar/data/1684144/000110465926122658/zom-ex31d2.htm
- Karen DeHaan-Fullerton, General Counsel. LinkedIn: https://linkedin.com/in/karen-dehaan-fullerton-47655545. Source: Form 4 filed Aug 7, 2026, https://www.sec.gov/Archives/edgar/data/1684144/000165495426007396/0001654954-26-007396-index.htm
- Russell Kevin Klass, Sr Vice President, Sales. Source: Form 4 filed Aug 7, 2026, https://www.sec.gov/Archives/edgar/data/1684144/000165495426007395/0001654954-26-007395-index.htm
- Chris MacLeod, Director. Source: 10-K filed Mar 16, 2026, https://www.sec.gov/Archives/edgar/data/1684144/000110465926028450/zom-20251231x10k.htm
- Jeffrey Rowe, Director. Source: 10-K filed Mar 16, 2026, https://www.sec.gov/Archives/edgar/data/1684144/000110465926028450/zom-20251231x10k.htm
- Johnny D. Powers, Director. Source: 10-K filed Mar 16, 2026, https://www.sec.gov/Archives/edgar/data/1684144/000110465926028450/zom-20251231x10k.htm
- Robert Cohen, Director. Source: 10-K filed Mar 16, 2026, https://www.sec.gov/Archives/edgar/data/1684144/000110465926028450/zom-20251231x10k.htm
- Rodney Williams, Director. Source: 10-K filed Mar 16, 2026, https://www.sec.gov/Archives/edgar/data/1684144/000110465926028450/zom-20251231x10k.htm

## Recent 8-K events

- Nov 4, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1684144/000165495426009511/zom_8k.htm
- Aug 5, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1684144/000165495426007306/zom_8k.htm
- Jun 11, 2026: Item 5.07, Submission of matters to a vote of security holders; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1684144/000165495426005904/zom_8k.htm
- May 6, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1684144/000165495426004419/zom_8k.htm
- Mar 16, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1684144/000165495426002304/zom_8k.htm
- Nov 4, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1684144/000165495425012575/zom_8k.htm
- Aug 6, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1684144/000165495425009136/zom_8k.htm
- Jun 11, 2025: Item 5.07, Submission of matters to a vote of security holders; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1684144/000165495425006839/zom_8k.htm
- May 15, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1684144/000165495425005749/zom_8k.htm
- Apr 30, 2025: Item 5.02, Departure or appointment of directors or officers; compensation; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1684144/000165495425004863/zom_8k.htm

## Insider trades (Form 4)

- May 21, 2026: Russell Kevin Klass (Sr. Vice President, Sales) bought 104,000 shares, about $10,400. Source: https://www.sec.gov/Archives/edgar/data/1684144/000165495426005315/0001654954-26-005315-index.htm
- May 20, 2026: Johnny D. Powers (Director) bought 200,000 shares, about $20,000. Source: https://www.sec.gov/Archives/edgar/data/1684144/000165495426005242/0001654954-26-005242-index.htm
- May 13, 2026: Johnny D. Powers (Director) bought 300,000 shares, about $33,000. Source: https://www.sec.gov/Archives/edgar/data/1684144/000165495426004895/0001654954-26-004895-index.htm
- May 11, 2026: Johnny D. Powers (Director) bought 500,000 shares, about $55,000. Source: https://www.sec.gov/Archives/edgar/data/1684144/000165495426004668/0001654954-26-004668-index.htm
- May 8, 2026: Larry C. Heaton Ii (CEO) bought 250,000 shares, about $27,500. Source: https://www.sec.gov/Archives/edgar/data/1684144/000165495426004631/0001654954-26-004631-index.htm
- Nov 13, 2025: Russell Kevin Klass (Sr Vice President, Sales) bought 150,000 shares, about $15,000. Source: https://www.sec.gov/Archives/edgar/data/1684144/000165495425013020/0001654954-25-013020-index.htm
- Nov 10, 2025: Russell Kevin Klass (Sr Vice President, Sales) bought 120,000 shares, about $12,000. Source: https://www.sec.gov/Archives/edgar/data/1684144/000165495425012794/0001654954-25-012794-index.htm
- Nov 7, 2025: Russell Kevin Klass (Sr Vice President, Sales) bought 5,000 shares, about $500. Source: https://www.sec.gov/Archives/edgar/data/1684144/000165495425012783/0001654954-25-012783-index.htm
- Nov 6, 2025: Russell Kevin Klass (Sr Vice President, Sales) bought 253,007 shares, about $20,241. Source: https://www.sec.gov/Archives/edgar/data/1684144/000165495425012706/0001654954-25-012706-index.htm
- Aug 12, 2025: Russell Kevin Klass (Sr Vice President, Sales) bought 1,056,064 shares, about $42,243. Source: https://www.sec.gov/Archives/edgar/data/1684144/000165495425009503/0001654954-25-009503-index.htm
- Aug 11, 2025: Russell Kevin Klass (Sr Vice President of Sales) bought 500,000 shares, about $20,000. Source: https://www.sec.gov/Archives/edgar/data/1684144/000165495425009402/0001654954-25-009402-index.htm
- Aug 8, 2025: Russell Kevin Klass (Sr Vice President of Sales) bought 500,000 shares, about $20,000. Source: https://www.sec.gov/Archives/edgar/data/1684144/000165495425009400/0001654954-25-009400-index.htm

## What management said

- "Zomedica delivered record third quarter revenue, continued year-over-year growth across our business, and made further progress in managing and improving upon operating costs and cash consumption" Larry Heaton, Chief Executive Officer of Zomedica (8-K filed Nov 4, 2026). Source: https://www.sec.gov/Archives/edgar/data/1684144/000165495426009511/zom_ex991.htm

## Latest filings

- 8-K filed Aug 5, 2026: https://www.sec.gov/Archives/edgar/data/1684144/000165495426007306/zom_8k.htm
- 10-K filed Mar 16, 2026: https://www.sec.gov/Archives/edgar/data/1684144/000110465926028450/zom-20251231x10k.htm
- 10-Q filed Aug 5, 2026: https://www.sec.gov/Archives/edgar/data/1684144/000110465926091075/zom-20260630x10q.htm
- DEF 14A filed Apr 27, 2026: https://www.sec.gov/Archives/edgar/data/1684144/000165495426003929/zom_def14a.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/